Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016', provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome) - The report reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Interstitial Cystitis (Painful Bladder Syndrome) therapeutics and enlists all their major and minor projects - The report assesses Interstitial Cystitis (Painful Bladder Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Interstitial Cystitis (Painful Bladder Syndrome) Overview 8 Therapeutics Development 9 Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview 9 Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis 10 Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies 11 Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes 12 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies 16 Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes 17 Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development 18 Allergan Plc 19 Aquinox Pharmaceuticals Inc. 20 Astellas Pharma Inc. 21 Kytogenics Pharmaceuticals, Inc. 22 Lipella Pharmaceuticals, Inc. 23 MediPost Co., Ltd. 24 UCB S.A. 25 Urigen Pharmaceuticals, Inc. 26 UroGen Pharmaceuticals, Ltd. 27 Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Combination Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 (heparin + lidocaine) - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 AQX-1125 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 ASP-6294 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Cartistem - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 certolizumab pegol - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 GM-0111 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 lidocaine hydrochloride - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 LP-08 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 mesalamine - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 MK-7264 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 NEO-5937 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 onabotulinumtoxinA - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 onabotulinumtoxinA SR - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 pentosan polysulfate sodium - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 URG-801 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects 77 Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products 78 Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones 79 Featured News & Press Releases 79 May 25, 2016: Aquinox Announces Executive Appointments 79 May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results 79 May 03, 2016: Allergan Presents New Data on LiRIS 400 mg at the American Urological Association Meeting in San Diego 81 Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA 81 Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration 82 Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference 82 Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis 83 Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS 84 Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 84 Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 84 Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis 85 May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms 85 Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis 86 Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome 87 Jun 02, 2014: Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND 88 Appendix 89 Methodology 89 Coverage 89 Secondary Research 89 Primary Research 89 Expert Panel Validation 89 Contact Us 89 Disclaimer 90
List of Tables
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2016 9 Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 18 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan Plc, H2 2016 19 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc., H2 2016 20 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Astellas Pharma Inc., H2 2016 21 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals, Inc., H2 2016 22 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals, Inc., H2 2016 23 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by MediPost Co., Ltd., H2 2016 24 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UCB S.A., H2 2016 25 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals, Inc., H2 2016 26 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016 27 Assessment by Monotherapy Products, H2 2016 28 Assessment by Combination Products, H2 2016 29 Number of Products by Stage and Target, H2 2016 31 Number of Products by Stage and Mechanism of Action, H2 2016 33 Number of Products by Stage and Route of Administration, H2 2016 35 Number of Products by Stage and Molecule Type, H2 2016 37 Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H2 2016 77 Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H2 2016 78
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
